Melanoma patients vaccinated with ALVAC

Melanoma patients were administered ALVAC canarypox virus containing a MAGE-A3 minigene, while others were vaccinated with MAGE-A3 peptide presented by HLA-A1, administered as peptide, and peptide-pulsed DCs. There was a correlation between tumor regression and detection of anti-MAGE-3.A1 CTL responses.

created over 15 years ago (4 March 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]